The need for disease-modifying therapies in Alzheimer's disease, and the strength of the case for aggregated beta-amyloid as a target, have recently driven substantial regulatory reform and innovations in clinical trial design to open up the path for faster and more effective human testing and approval of novel Alzheimer's therapeutics. The first fruits of these changes are a series of large, late-stage clinical trials of immunotherapies targeting the removal of beta-amyloid from the brain. These reforms and precedents open up the path for human testing and approval of future rejuvenation biotechnologies.
We all know that mitochondria are the cell's "powerhouse" for energy. One interesting fact about these organelles is that they have their own DNA in addition to the nuclear DNA that we are all aware of. However, the mitochondrial DNA is prone to mutations due to constant exposure from reactive oxygen species because it is not encased in a nuclear envelope nor does it have efficient repair mechanisms to correct mutations as they occur. Amutha Boominathan explains how moving the mitochondrial genes to the nucleus, where it's safer to express them for function, would let mitochondria keep producing energy normally, even after mitochondrial mutations have occurred.
Jayanthi Vengalam explains her work with the Mitochondrial Mutation team, with consequences for acute diseases such as diabetes, Parkinson's and Alzheimer's
At just 15, Thomas Hunt became the youngest 20Under20 Finalist selected by Peter Thiel's Foundation to compete for a $100,000 Fellowship and the chance at two years of freedom to pursue his dreams. But Thomas’s entire story is even more amazing. He's been conducting research here at SENS Research Foundation in Mountain View since the age of 13.
While antibiotics have long provided broad-spectrum treatments for bacterial infections, antiviral drugs have failed to offer protection that is nearly as wide. Dr. Todd Rider, who will be speaking at SENS6, is working to change that.
Jennie explains her internship with SENS Research Foundation (SRF) in Mountain View, CA, attempting to identify genes involved in the Alternative Lengthening of Telomeres (ALT) Mechanism.
Many diseases mirror some aspect of aging. Multiple sclerosis (MS), which is caused by the loss of the myelin coating that protects nerve cells in the brain and spinal cord, is one example: myelin is also lost and poorly replaced in normal aging. Scientists like Cambridge’s Dr. Robin Franklin, a SENS6 speaker, are working hard to repair this damage.
Introduction to Dr. Alan Russell and his work crossing the boundaries of chemical engineering, biology, and materials science.
Our next intern Connie Wang explains her part in uncovering the complex links between microglia cells and Alzheimer's disease.
Haroldo Silva explains why he joined OncoSENS team at the SRF Research Center and explains the role of telomere lengthening in cancer.